Approval · Notice of Compliance 31873 · 2023
MINT-EZETIMIBE: Notice of Compliance 31873
Issued October 17, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31873
- Date
- October 17, 2023
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to Labels. Administrative: Labelling Update (to match Licensor)
- Canadian reference product
- EZETROL (Merck Frosst)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-EZETIMIBE | Not yet assigned | — |
Medicinal ingredients
- EZETIMIBE 10 MG per TAB